FIGURE 1.

Multi‐target therapeutic strategy for COVID‐19‐related multiple health complications by dual inhibition of CB₁ receptors and iNOS. (a) Dual inhibition of CB₁ receptors (CB₁R) and iNOS may not only attenuate acute COVID‐19 complications such as acute respiratory distress syndrome (ARDS), septicaemia, heart failure, acute kidney injury, endothelial dysfunction and thrombosis but may also mitigate the development of pulmonary fibrosis as a late sequela of COVID‐19. (b) Both CNR1 and NOS2 gene expression are increased in lungs of COVID‐19 patients. Lung expression profiles of CNR1 and NOS2 were retrieved from RNAseq data set (Desai et al., 2020) from five virus‐negative controls, seven COVID cases with low viral load and eight COVID cases with high viral load. Multiple data points obtained from different lung lobes were used for COVID cases considering temporal and spatial heterogeneity of host response to SARS‐CoV‐2 infection. The figure was generated in Biorender.com